CHiRP Study: Utilizing RaDaR® for recurrence monitoring in HR+, HER2- breast cancer


Watch this short video discussing the CHiRP Study, which evaluated circulating tumor DNA (ctDNA) and late recurrence in high-risk hormone receptor positive, HER2-negative breast cancer. (Lipsyc-Sharf et al. Journal of Clinical Oncology 2022)

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients